We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+14.02%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.23B
AUM Growth
+$101M
Cap. Flow
-$21.8M
Cap. Flow %
-1.78%
Top 10 Hldgs %
30.12%
Holding
96
New
14
Increased
27
Reduced
30
Closed
13

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$23.4M
2
ABBV icon
AbbVie
ABBV
+$21.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$17M
4
MRK icon
Merck
MRK
+$14.7M
5
CVS icon
CVS Health
CVS
+$11.7M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$39.6M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$25.9M
3
LVGO
Livongo Health, Inc. Common Stock
LVGO
+$23.4M
4
IMMU
Immunomedics Inc
IMMU
+$18.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%
2 Industrials 0.53%
3 Communication Services 0%
4 Consumer Discretionary 0%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
51
DELISTED
Exact Sciences
EXAS
$9.94M 0.81%
75,000
-5,000
-6% -$605K
BIIB icon
52
Biogen
BIIB
$30.2B
$9.79M 0.8%
40,000
+7,000
+21% +$1.81M
GKOS icon
53
Glaukos
GKOS
$10.7B
$9.41M 0.77%
125,000
-15,000
-11% -$948K
RDUS
54
DELISTED
Radius Health, Inc.
RDUS
$8.61M 0.7%
481,826
+150,000
+45% +$2.25M
SILK
55
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.87M 0.64%
125,000
-15,000
-11% -$931K
MGTX icon
56
MeiraGTx Holdings
MGTX
$1.19B
$6.81M 0.56%
450,000
+75,000
+20% +$1.06M
ADVM
57
DELISTED
Adverum Biotechnologies
ADVM
$6.78M 0.55%
62,500
– –
ACCD
58
DELISTED
Accolade Inc
ACCD
$6.53M 0.53%
150,000
-1,674
-1% -$74.3K
RVNC
59
DELISTED
Revance Therapeutics, Inc.
RVNC
$6.24M 0.51%
220,000
– –
SWAV
60
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$6.22M 0.51%
60,000
– –
RIGL icon
61
Rigel Pharmaceuticals
RIGL
$779M
$6.08M 0.5%
173,618
– –
PHAT icon
62
Phathom Pharmaceuticals
PHAT
$699M
$5.81M 0.47%
+175,000
New +$7.09M
ISRG icon
63
Intuitive Surgical
ISRG
$141B
$5.73M 0.47%
21,000
-15,000
-42% -$3.72M
AGIO icon
64
Agios Pharmaceuticals
AGIO
$1.96B
$5.63M 0.46%
130,000
+40,000
+44% +$1.58M
MYOV
65
DELISTED
Myovant Sciences Ltd.
MYOV
$5.52M 0.45%
200,000
-180,000
-47% -$3.5M
KYNB
66
Kyntra Bio
KYNB
$28.9M
$5.38M 0.44%
5,800
– –
ARNA
67
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.38M 0.44%
70,000
-140,778
-67% -$10.6M
GTHX
68
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$4.32M 0.35%
240,000
+50,000
+26% +$747K
FPRX
69
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$4.25M 0.35%
+250,000
New +$3.13M
ALKS icon
70
Alkermes
ALKS
$8.25B
$4.18M 0.34%
209,354
-100,646
-32% -$1.84M
DVAX
71
DELISTED
Dynavax Technologies
DVAX
$4.12M 0.34%
925,534
– –
OSH
72
DELISTED
Oak Street Health, Inc.
OSH
$3.67M 0.3%
+60,000
New +$3.15M
DCPH
73
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.42M 0.28%
+60,000
New +$3.56M
ANNX icon
74
Annexon
ANNX
$855M
$3.25M 0.27%
+130,000
New +$3.35M
VRAY
75
DELISTED
ViewRay, Inc.
VRAY
$2.96M 0.24%
775,000
– –
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rhenman & Partners Asset Management held 96 positions worth $1.23B, up 9% from $1.12B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q4 2020 filing shows 14 new, 27 increased, 30 reduced and 13 closed positions. Its largest new stake was Teladoc Health: 115,000 shares worth $23M. The largest sale was NovoCure, an estimated $39.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials and Communication Services.

  • Rhenman & Partners Asset Management's largest Q4 2020 buy was Teladoc Health: 115,000 shares worth $23M.
  • Rhenman & Partners Asset Management added most to AbbVie in Q4 2020, an estimated $21.1M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2020 reduction was NovoCure, cutting an estimated $39.6M.
  • Rhenman & Partners Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $25.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $1.23B portfolio in Q4 2020.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 13 in Q4 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 9% quarter-over-quarter to $1.23B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2020, filed 19 Jan 2021.